Heart transplant recipient battles insurer to retain life-saving anti-rejection drug
Payton Herres received a heart transplant at age 11 due to a congenital condition called Ebstein's anomaly. Fifteen years after her surgery, she found herself unable to access everolimus, the anti-rejection medication she had depended on since 2013. Her insurer stopped covering the drug, and its out-of-pocket cost became unaffordable. Herres shared her situation on social media, where her story gained widespread attention. Entrepreneur Mark Cuban's pharmacy company stepped in to supply the medication at a significantly reduced price.
This is an AI-generated summary. ShortSingh links to the original source for the complete article.



Discussion (0)
Log in to join the discussion and vote.
Log in